The making of deals that help advance research or license products in the UK pharmaceutical industry fell 18 per cent in 2011, a report by consultancy PharmaVentures has found.
According to the firm, the low figures were a result of companies cutting R&D expenditure and streamlining their research and development activities.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.